appScorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Alembic Pharmaceuticals Ltd
APLLTD
Price Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key MetricsEdit
Forecast & RatingsDetailed Forecast
Analysts have suggested that investors can buy this stock
Company Profile
Alembic Pharmaceuticals Limited is a pharmaceutical company engaged in developing formulations and active pharmaceutical ingredients (API).
Investor PresentationView older
View Older PresentationsPeersCompare with peers
Sun Pharmaceutical Industries Ltd
Cipla Ltd
Dr Reddy's Laboratories Ltd
Mankind Pharma Ltd
Torrent Pharmaceuticals Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Financial TrendFinancial statements
Holdings TrendDetailed holdings
Low Pledged Promoter HoldingLower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
Mutual Fund HoldingIncreasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock
In last 3 months, mutual fund holding of the company has almost stayed constant
Recent NewsAll news
Alembic Pharma - U.S. Sales, Profitability To Improve: Prabhudas Lilladher
1 month ago•Bloomberg Quint
Alembic, Aurobindo recall drugs in US market
1 month ago•Economic Times
Alembic aims for US rebound with new launches
1 month ago•Economic Times
Reduce Alembic Pharma; target of Rs 705: ICICI Securities
1 month ago•Moneycontrol
Broker’s call: Alembic Pharma (Buy)
1 month ago•The Hindu Businessline
Q1 Review: Alembic Pharmaceuticals EBITDA Rises Multifold YoY
1 month ago•Bloomberg Quint
Alembic Pharma Q1 Results Review - Execution Remains A Key: Dolat Capital
1 month ago•Bloomberg Quint
Alembic Pharma posts Rs 121 crore net profit in Q1FY24
1 month ago•Economic Times
Alembic Pharmaceuticals Revenue Up By 18% To ₹1486 Cr In Q1FY24
1 month ago•Free Press Journal
Alembic Pharma Q1 Results: Firm posts profit on strong sales
1 month ago•Economic Times
Recent EventsAll events
Spurt in Volume
Significant increase in volume has been observed in Alembic Pharmaceuticals Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Alembic Pharmaceuticals Limited has submitted their response. | Download
Significant increase in volume has been observed in Alembic Pharmaceuticals Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Alembic Pharmaceuticals Limited has submitted their response. | Download
Cash Dividend
Final • Div/Share: ₹ 8
Total Promoter HoldingIncreasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant